Cardiac resynchronization therapy in patients with heart failure
systematic review
Keywords:
Heart failure, Heart conduction system, Bundle-branch block, Pacemaker, artificial, MortalityAbstract
CONTEXT AND OBJECTIVE: Cardiac resynchronization therapy (CRT) has emerged as the predominant electrical treatment strategy for patients on pharmacological therapy who present heart failure with wide QRS and low ejection fraction. The objective of this study was to investigate whether cardiac resynchronization therapy improved mortality and morbidity among patients with heart failure. METHODS: This was a systematic review using the Cochrane Collaboration’s methodology. The online search strategy included the Cochrane Library, Medline (Medical Literature Analysis and Retrieval System Online), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde) and cardiology congresses from 1990 to 2006. The criteria for considering studies for this review were as follows:-types of studies: randomized controlled trials; types of interventions: cardiac resynchronization therapy compared with other therapies; types of participants: patients with heart failure with low ejection fraction and wide QRS; outcomes: death or hospitalization. RESULTS: Seven trials met the selection criteria. The risk of death due to congestive heart failure was nonsignificant: relative risk (RR), 0.79; 95% confidence interval (CI): 0.60 to 1.03. There was an absolute risk reduction of 4% in all-cause mortality for the experimental group [RR 0.70; CI: 0.60 to 0.83; number needed to treat (NNT) 25]; sudden cardiac death showed a statistically significant difference favoring the experimental group, with absolute risk reduction of 1% (CI: 0.46 to 0.96; RR 0.67; NNT 100). There was an absolute risk reduction of 9% for hospitalization due to heart failure (RR 0.64; CI: 0.50 to 0.80; NNT 11) in the experimental group. CONCLUSIONS: Patients receiving CRT had a significantly lower risk of hospitalization due to heart failure, but death rates due to heart failure were similar.
Downloads
References
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A.
Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-151.
O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13(4):S107-12.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429-35.
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrener- gic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98(12):1184-91.
Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angioten- sin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23)1667-75.
Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta- analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39(3):463-70.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.
Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med. 2001;161(19):2337-42.
Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflam- matory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002;162(3):265-70.
Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modifica- tion by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73(2):257-67.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions
2.6 [updated September 2006]. In: The Cochrane Library, Issue 4. Chichester: John Wi- ley & Sons, Ltd; 2006. Available from: http://www.cochrane.org/resources/handbook/ Handbook4.2.6Sep2006.pdf. Accessed in 2008 (Nov 4).
Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845-53.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or wi- thout an implantable defibrillator in advanced chronic heart failure. N Engl J Med.2004;350(21):2140-50.
Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344(12):873- 80.
Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbi- dity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49.
Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42(8):1454-9.
Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23(22):1780-7.
Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implan- table cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289(20):2685-94.
McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141(5):381-90.
Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from right ventricular pacing to bi- ventricular pacing in previously paced patients with advanced heart failure: A randomized controlled study [the RD-CHF Trial] [Abstract 1965]. Presented at the European Society of Cardiology Congress, Vienna, Austria, August 30 – September 3, 2003.
Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289(6):730-40.
Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analy- sis of randomized controlled trials. Eur Heart J. 2006;27(22):2682-8.
